NCT02908269View on ClinicalTrials.gov

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

PHASE4CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

December 9, 2016

Study Completion Date

December 9, 2016

Conditions

Influenza

Interventions

BIOLOGICAL

Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone High-Dose, vaccine, 2016-2017 formulation

0.5 mL, Intramuscular

Trial Locations (2)

40004

Bardstown

70002

Metairie

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02908269 - Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations | Biotech Hunter | Biotech Hunter